Image 1
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 0228-2891
19 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 0228-2891). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image 10
Line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine at doses of 20 mg, 60 mg, and 120 mg once daily with placebo, with the percentage of patients improved decreasing as the percent improvement in pain increases.*
Image 11
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine delayed-release 60/120 mg once daily. The graph shows two lines: one with diamonds representing Duloxetine patients and another with crosses representing placebo patients, illustrating patient response distribution across different pain improvement thresholds.*
Image 12
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Duloxetine Delayed-Release 60 mg once daily with placebo across various pain improvement thresholds. Duloxetine shows a higher percentage of patients improved relative to placebo at most improvement levels.*
Image 13
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine delayed-release 60/120 mg once daily. The graph shows two lines, one for placebo and one for Duloxetine, indicating patient outcomes at various pain improvement thresholds.*
Image 14
Image 15
Image 16
Image 17
Label for Duloxetine Delayed-Release Capsules, USP 20 mg, showing a package containing 60 capsules. The label includes dosage form as delayed-release capsules and highlights pharmacist instructions to dispense the accompanying medication guide. It also features storage instructions, manufacturing details by Teva Pharmaceuticals, and barcodes.*
Image 18
Label for Duloxetine Delayed-Release Capsules USP, 30 mg strength, in a package of 30 capsules. The label includes dosage and storage instructions, a note to dispense the accompanying Medication Guide, and mentions the manufacturer as Teva Pharmaceuticals, Parsippany, NJ. The label features the NDC number 0228-2891-03 and a barcode.*
Image 19
Label for Duloxetine Delayed-Release Capsules USP, 60 mg strength, in a package of 30 capsules. The label includes dosage instructions, storage conditions, and manufacturer information for Teva Pharmaceuticals, Parsippany, NJ. It features the Teva logo and a barcode with serialization coding area.*
Image 2
Image 3
Image 4
Chemical structure diagram of duloxetine hydrochloride, showing its molecular framework including a thiophene ring, naphthyl group, and methylamine group bonded to hydrochloride.*
Image 5
Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) between placebo and Duloxetine delayed-release capsules treatment groups. The graph shows time from randomization on the x-axis and proportion of patients with relapse on the y-axis, illustrating lower relapse proportion with Duloxetine compared to placebo over the study period.*
Image 6
A Kaplan-Meier plot depicting the proportion of patients with relapse over time (days) from randomization, comparing placebo and duloxetine delayed-release capsules. The graph shows treatment groups with placebo indicated by a dashed line and duloxetine by a solid line, illustrating differences in relapse rates across approximately 300 days.*
Image 7
A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. Four lines represent different groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The y-axis shows percentage of patients improved, and the x-axis shows percent improvement in pain from baseline.*
Image 8
A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing trends of patient improvement across increasing pain relief percentages.*
Image 9
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, once daily, and placebo. The vertical axis shows percentage of patients improved, while the horizontal axis shows percent pain improvement, illustrating treatment effects over different pain improvement levels.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
